The global trial aims to enroll about 4,000 pregnant women ages 18 and older vaccinated during 24 to 34 weeks of gestation.
Prior to conducting the trial, regulatory authorities required Pfizer and BioNTech to complete a developmental and reproductive toxicity study with their COVID-19 vaccines. The drugmakers said the studies showed no evidence of fertility or reproductive toxicity in animals.
The trial announcement comes a week after National Institutes of Health researchers urged drugmakers developing COVID-19 vaccines to conduct more research on the vaccines’ safety and efficacy in pregnant recipients.
“Pregnant and lactating persons should not be protected from participating in research, but rather should be protected through research,” they wrote in an article published Feb. 10 in JAMA.
More articles on pharmacy:
NIH to study remdesivir as COVID-19 treatment in pregnant women
US vaccinating average of 1.7M people per day
Pfizer COVID-19 vaccine less potent against South Africa variant, preliminary study says
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
